Sort by
Refine Your Search
-
directly from the letter writer to PharmDFellowships@northeastern.edu by November 21, 2025. LOR writers must include the candidate's name and the fellowship program(s) in the subject line (e.g., Smith, John
-
@northeastern.edu by November 21, 2025. LOR writers must include the candidate’s name and the fellowship program(s) in the subject line (e.g., Smith, John – Alnylam, GSK). Address cover letter and letters of
-
to collaborate with Prof. Robert Riener at ETH Zürich, a leader in Rehabilitation Robotics. Projects span human subjects research, computational modeling, and robotic technologies. This position is ideal
-
Internal Number: 6579360 Ironwood Pharmaceuticals-Regulatory Affairs Postdoctoral Research Fellow About the Opportunity Program Overview Northeastern University Pharmaceutical Industry Fellowships Program is
-
) should be sent directly from the letter writer to PharmDFellowships@northeastern.edu by November 21, 2025. LOR writers must include the candidate’s name and the fellowship program(s) in the subject line
-
letter writer to PharmDFellowships@northeastern.edu by November 21, 2025. LOR writers must include the candidate’s name and the fellowship program(s) in the subject line (e.g., Smith, John – Alnylam, GSK
-
directly from the letter writer to PharmDFellowships@northeastern.edu by November 21, 2025. LOR writers must include the candidate’s name and the fellowship program(s) in the subject line (e.g., Smith
-
writers must include the candidate’s name and the fellowship program(s) in the subject line (e.g., Smith, John – Alnylam, GSK). Address cover letter and letters of recommendation to: J. Andrew Orr-Skirvin
-
to PharmDFellowships@northeastern.edu by November 21, 2025. LOR writers must include the candidate's name and the fellowship program(s) in the subject line (e.g., Smith, John - Alnylam, GSK). Address cover letter and
-
name and the fellowship program(s) in the subject line (e.g., Smith, John - Alnylam, GSK). Address cover letter and letters of recommendation to: J. Andrew Orr-Skirvin, PharmD, BCOP Clinical Professor